成都明晟持有近两千万股 每经记者｜鄢银婵 每经编辑｜魏官红 2026年1月8日，深圳市精锋医疗科技股份有限公司（以下简称精锋医疗，证券简称精锋医疗-B，HK02675，股价58.050港元，市值 225.070亿港元）正式登陆港交所主板。上市首日，公司股价涨超30%，盘中最高达60.000港元/股，截至当日收盘，精锋医疗股价为 56.600港元/股。 每经媒资库图 《每日经济新闻》记者注意到，这家由"85后"博士夫妇创办的企业，在成立不足9年的时间里，完成了从10万元启动资金到估值超百亿 元的跨越，其有3款产品已经获批，核心产品多孔腔镜手术机器人已在国内获批，用于泌尿外科、妇科、普外科及胸外科手术，累计签 约销量达61台，覆盖全球20余个国家。 不过，作为产品商业化起步不久的公司，精锋医疗同样面临常年亏损、市场竞争愈发激烈的问题。一方面，核心产品赛道已有10余款 产品厮杀；另一方面，面对已实现国产化的达芬奇系统，其"价格优势"不及从前。 1月12日，精锋医疗股价上涨3.66%。 2017年5月4日，王建辰和高元倩夫妇在深圳认缴出资10万元，注册成立了精锋医疗。 这对创始人还是大学同学，两人分别在2013年和2 ...

控制系统优化：团队通过对主手的高精度运动学与动力学建模，实现了操作的轻便与流畅，重点解决了以钢带或钢丝传动的手术器械在运动补偿和间隙控制 方面的核心难题。 系统性能提升：通过多环节协同优化，系统整体延迟控制在80毫秒以内。视频系统实现了40毫秒内完成4K荧光信号的采集与传输，同时通过结构设计与运 动控制算法的联合补偿，有效抑制了机械传动中的间隙与弹性变形。 来源：猎云网 12月31日，杭州康基唯精医疗机器人有限公司（以下简称"唯精医疗"）宣布，已完成亿元级B+轮融资。本轮融资获得了国泰海通证券旗下国泰君安创新投 资有限公司的独家投资，同时战略股东康基医疗继续追加投资，歌路资本担任本次交易的独家财务顾问。 此次募集资金将主要用于加速产品商业化进程，并推动新一代产品的研发与临床注册。 唯精医疗的核心团队源自哈尔滨工业大学机器人技术与系统全国重点实验室，是业内鲜有的、连续承担国家"十一五"至"十三五"系列863计划及重点研发计 划微创手术机器人项目的团队。 围绕外科手术中"看不清"与"做不到"的临床痛点，唯精医疗打造了极具竞争力的产品矩阵，在技术层面实现了多项重大突破： 手术体验革新：产品通过双目 4K显示与延迟低 ...

深圳市精鋒醫療科技股份有限公司 Shenzhen Edge Medical Co., Ltd. 股份代號 : 2675 （於中華人民共和國註冊成立的股份有限公司） 全球發售 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示： 閣下如對本文件的任何內容有任何疑問，應尋求獨立專業意見。 Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售項下的發售股份數目 | ： | 27,722,200股H股（視乎超額配股權行使 | | --- | --- | --- | | 與否而定） | | | | 香港發售股份數目 | ： | 2,772,300股H股（可予重新分配） | | 國際發售股份數目 | ： | 24,949,900股H股（可予重新分配及視乎 | | 超額配股權行使與否而定） | | | | 發售價 | ： | 每股H股43.24港元，另加1.0%經紀 | ...

12月26日，杭州康基唯精医疗机器人有限公司宣布已完成亿元级B+轮融资。本轮融资获得了国泰君安 创新投资有限公司的独家投资，同时战略股东康基医疗继续追加投资，歌路资本担任本次交易的独家财 务顾问。此次募集资金将主要用于加速产品商业化进程，并推动新一代产品、功能的研发与临床注册。 唯精医疗公司核心团队源自哈尔滨工业大学机器人技术与系统全国重点实验室，从2003年在哈工大实验 室开始基础研究，到如今产品进入全国顶尖医院临床应用，这二十年来，团队累计申请专利400余项。 （唯精医疗） 此外，唯精医疗在具身智能领域持续深耕，尤其在远程手术与人工智能术中导航等前沿方向，公司研发 团队紧密围绕临床实际需求与行业难点，开展了具有差异化的创新研发。例如，其术中导航系统能够对 关键解剖结构进行实时识别与提示，帮助外科医生精准规划手术路径，从而有效规避术中风险，显著提 升了手术的安全性及操作精度。 唯精医疗的核心产品四臂腹腔镜手术机器人（国械注准20253010806）已于2025年4月获得注册证，标志 着国产手术机器人正式进入规模化临床应用新阶段。临床数据显示无一例需要中转开展传统开腹手术， 这一数据无可辩驳地证明了系统在处理 ...

文章来源： 微创机器人 转载要求：可以直接转载，请在文首注明来源 2025 年 12 月 24 日 ， 国 产 图 迈 ® 腔 镜 手 术 机 器 人 正 式 落 地 巴 西 Hospital Unimed Foz do Iguaçu。 这是 图迈 ® 机器人在全球范围的 第 100 台 商业化装机， 该百台装机均已取得用户签 署的装机验收报告。该等交易安排均符合公司收入确认政策，完成收入确认。公司的收入确认政策 遵循香港会计准则与行业惯例。 截至目前， 图迈 ® 机器人全球累计订单量突破 160+ 台 ，微创 ® 机器人集团旗下腔镜、骨科、血管介入核心产品综合订单量累计突破 230 台 ，各产品共完成商 业化装机 150 余台 。 图迈 ® 机器人成为首个实现100台商业化装机的国产腔镜手术机器人，不仅证明其已具备行业基础 设施级的系统可靠性与临床稳定性，也标志着其在质量合规、生产工艺、工程验证、系统交付、临 床适配及全流程保障能力等关键体系上实现了全面跃升。 微创 ® 机器人集团总裁何超博士指出， 图迈 ® 全球市场份额持续跃升，标志着中国不再是全球医疗技术创新叙事的旁观者，而是成为推动 全球手术技术普惠 ...

Core Viewpoint - The article emphasizes the advancements in healthcare services in Fujian, particularly focusing on high-level hospitals and specialized medical centers, aiming to provide top-tier medical treatment locally and enhance patient satisfaction [5][9]. Group 1: Heavy Ion Therapy - The first heavy ion therapy device in Fujian is operational at the Fujian Medical University Affiliated Union Hospital, providing cutting-edge cancer treatment [6]. - Heavy ion therapy utilizes carbon ions accelerated to 40%-70% of the speed of light, creating a "Bragg peak" effect that allows for precise targeting of tumor cells while minimizing damage to surrounding healthy tissue [6][7]. - Patients report minimal discomfort during treatment, with some able to rest during the procedure, highlighting the efficiency and patient-friendly nature of this advanced therapy [6]. Group 2: Multidisciplinary Treatment Approach - The hospital is integrating various specialties to create a multidisciplinary treatment model, which is crucial for managing complex medical cases [9][11]. - A case study illustrates the successful collaboration among cardiology, neurology, and surgery teams to treat a patient with multiple severe conditions, showcasing the effectiveness of this approach [10][11]. - The hospital's heart center has restructured its teams into specialized groups to enhance patient care and streamline treatment processes [12]. Group 3: Remote Surgery Innovations - The first cross-province remote robotic surgery was successfully performed, demonstrating the potential of telemedicine to provide high-quality care regardless of location [13]. - This technology allows local doctors to assist in surgeries performed by experts from distant locations, enhancing their skills and improving patient outcomes [14]. - The integration of remote surgery aligns with national healthcare policies aimed at optimizing medical resources and improving access to care for patients in rural areas [16].

革新减重外科 近日，树兰（济南）医院院长胡三元教授团队，通过无形的5G网络与灵活的机器人机械臂协同，完成 了全国首例5G远程机器人袖状胃切除术。这标志着我国在减重与代谢外科这一重要领域，正式迈入 了"超远程精准手术"的新纪元，为破解医疗资源分布不均难题提供了极具价值的"山东实践"。这次手术 的成功，标志着优质医疗资源能够突破时空限制，通过网络技术实现"零延迟"精准输送。 袖状胃切除术是一种兼具减重与代谢改善效果的微创外科手术。其核心原理是将原本呈"储物袋"状、可 高度扩张的胃沿纵轴切除约80%，只保留一条类似"香蕉"或"袖子"的细长管状胃腔。这种结构变化带来 三重作用：显著减少胃容量、不改变胃肠道生理通路、调节关键代谢激素。手术切除的是胃底部产生饥 饿素（Ghrelin）的主要区域，使饥饿感显著下降，同时可提升 GLP-1、PYY 等肠促胰素水平，从而改 善胰岛功能、降低血糖、促进代谢稳态恢复。因此，袖状胃切除术不仅通过"减少能量摄入"实现减重， 更通过"重塑激素调控"改善代谢，是当前临床上效果稳定、安全性高的减重代谢手术方式之一。 云端执刀 本次手术的成功，不仅是技术的胜利，更是协作模式的创新。它确立了"远 ...

Core Viewpoint - The medical robotics industry is positioned as a strategic high ground in global technological competition, driven by the acceleration of a new round of technological revolution and industrial transformation, alongside the increasing aging population in China and the continuous improvement of the hierarchical medical system [1] Group 1: Industry Development - The Ministry of Industry and Information Technology (MIIT) will promote high-quality development of the medical robotics industry, emphasizing top-level design and the formulation of the "14th Five-Year" high-end medical equipment industry development plan, with medical robots as a key development area [1] - A comprehensive policy system will be established to support technological innovation, registration and certification, medical insurance pricing, and application promotion for medical robots [1] Group 2: Innovation and Technology - MIIT supports collaboration among industry, academia, research, and medical sectors to accelerate the research and development of key common technologies such as bionic intelligent materials and flexible sensors [1] - The focus will be on clinical needs in specific areas like interventional radiology and dental implants, aiming to develop innovative products and promote the integration of 5G and artificial intelligence with medical robots [1] - New models and business formats such as remote surgery and AI-assisted diagnosis will be cultivated [1]

Core Viewpoint - The successful completion of the world's first remote robotic retinal injection surgery in Xinjiang marks a significant advancement in telemedicine, showcasing the capabilities of domestic surgical robots and the potential for remote surgeries to become practical and safe in the near future [1][3][5]. Group 1: Technological Breakthroughs - The remote robotic retinal injection surgery took only seven minutes and required precision at the micrometer level, highlighting the complexity and difficulty of such procedures [3][5]. - The transition from "centimeter-level" remote surgeries to "micrometer-level" surgeries represents a qualitative leap in surgical precision [6]. - The collaboration between medical teams and engineers has led to customized solutions that enhance the stability and accuracy of domestic surgical robots [6]. Group 2: Clinical Applications and Challenges - Despite breakthroughs, most remote robotic surgeries are still in clinical trial phases and have not yet achieved large-scale clinical application [6]. - The implementation of remote surgeries can alleviate the burden of long-distance travel for patients, but concerns about safety and standardization remain [7][10]. - The establishment of operational guidelines, such as the "Remote Robotic Surgery Operation Guidelines (2025 Edition)," aims to address safety and regulatory concerns [15][17]. Group 3: Regional Healthcare Impact - Remote surgeries enable the sharing of high-quality medical resources across provinces, as demonstrated by the successful remote surgery conducted from Guangzhou to Xinjiang [12]. - The goal is to replicate successful models in remote areas, ensuring that patients in less developed regions receive top-tier medical services [14]. - The integration of remote surgery into local healthcare systems requires significant investment in training and equipment, which poses challenges for grassroots medical institutions [20][27]. Group 4: Future Directions - The ongoing development of domestic surgical robots is expected to lower costs, making them more accessible to grassroots healthcare facilities [29]. - Innovations in technology must be accompanied by reforms in medical regulations, including clarifying responsibilities and compensation for healthcare providers involved in remote surgeries [29].

Group 1: Surgical Robotics - A record-breaking remote robotic surgery was successfully performed over a distance of 12,035 kilometers, certified by Guinness World Records as the "farthest distance for remote robotic surgery" [2] - The surgery was conducted by Dr. Leandro Totti in Kuwait using the Chinese-developed Jingfeng® surgical robot, demonstrating a bidirectional communication delay of only 199 milliseconds, ensuring precision and safety during the procedure [4] Group 2: Pharmaceutical Innovations - The first AI-enabled formulation drug in China, MTS-004, has successfully reached the primary endpoint of Phase III clinical trials, marking a significant milestone in the pharmaceutical industry [6] - MTS-004 is designed for the treatment of Pseudobulbar Affect (PBA) and features an orally disintegrating tablet formulation that improves patient compliance by dissolving quickly in the mouth without water [8] Group 3: Medical Devices - The GuiTracker® hard guidewire developed by Shanghai Shape Memory Alloy Materials Co., Ltd. has received approval for market launch, aimed at enhancing the performance of cardiovascular and peripheral vascular interventional surgeries [10] - The guidewire addresses clinical challenges by providing high support and stability, crucial for navigating complex vascular conditions during procedures [10] Group 4: Advanced Therapies - C-CAR168, a novel CAR-T therapy developed by Xibiman Biotechnology, has been selected as a breakthrough abstract for the 2025 American College of Rheumatology (ACR) Convergence, highlighting its potential in treating refractory autoimmune diseases [12][13] Group 5: Brain Research Initiatives - The China Brain Multi-omics Atlas Project (CBMAP) has officially launched, aiming to create a comprehensive molecular map of the human brain, focusing on the East Asian population [15] - M20 Genomics' VITA high-throughput single-cell full-length transcriptome platform has been chosen as a core method for this project, enabling high-quality analysis of precious brain tissue samples [19] Group 6: Medical Materials - The animal study results of UniPearls®, a new generation drug-loaded embolic microsphere, have been published in a leading biomaterials journal, demonstrating its effectiveness and safety for use in transarterial embolization [21][24] Group 7: Investment Landscape - Sequoia China has invested in over 200 innovative healthcare companies, covering various sectors including innovative drugs, medical devices, and digital healthcare, with more than 45 companies having completed IPOs [25]